cotrimoxazol (trimethoprim + sulfamethoxazol)
Safety margins
Weight | ROA | Dosage |
---|---|---|
ROA: po |
Dosage: min. 400/80mg 1 dd to max. 1600/320mg 3 dd |
|
ROA: iv |
Dosage: min. 400/80mg 1 dd to max. 1600/320mg 3 dd |
Kidney function
ROA | GFR | Dosage | Interval | Comments |
---|---|---|---|---|
ROA: po | ||||
GFR: 10 - 30 |
Dosage: 50% |
|||
GFR: <10 |
Dosage: do not prescribe |
|||
ROA: iv | ||||
GFR: 10 - 30 |
Dosage: 50% |
|||
GFR: <10 |
Dosage: do not prescribe |
Notes GFR general:
Volwassenen: bij PCP:
normale nierfunctie: 25/5 mg/kg 3 dd iv/po.
GFR 50-100 ml/min: 25/5 mg/kg 2-3 dd iv/po.
GFR 10-50 ml/min: 25/5 mg/kg 1-2 dd iv/po.
GFR < 10 ml/min: 12.5/2.5 mg/kg 1 dd iv/po.
Renal function-replacement therapy
CAPD: not dialized - Cotrimoxazol wordt niet of nauwelijks verwijderd door peritoneale dialyse. 800 mg sulfamethoxazol + 160 mg trimethoprim 1x per dag. PCP: 12.5/2.5 mg/kg 1 dd iv/po. Bij behandeling langer dan 1 week monitor de N4-acetylmetaboliet
Hemo dialysis: Intermitterende hemodialyse: 800 mg sulfamethoxazol + 160 mg trimethoprim 1x per dag, op dialysedagen toedienen na de dialyse. PCP: 12.5/2.5 mg/kg na elke dialyse iv/po. Monitor de N4-acetylmetaboliet.
CAV / VVHD: Continue hemodialyse: 1600 mg sulfamethoxazol + 320 mg trimethoprim 3x per dag gedurende de eerste 48h (72h bij PCP). Vervolgens 1600 mg SMX + 320 mg TMP 1x per dag (2x per dag bij PCP). Vanaf dag 4 op geleide van spiegels. Monitor de N4-acetylmetaboliet
Interactions
Interaction with (ATC): | Expected effect: |
---|---|
Interaction with (ATC): L04AD01 - Ciclosporin |
Expected effect: verlaging ciclosporineconcentratie in volbloed en verhoogde kans op nefrotoxiciteit |
Interaction with (ATC): N03AB02 - Phenytoin |
Expected effect: verhoging plasmaconcentratie fenytoine |
Interaction with (ATC): B03BB01 - Folic Acid |
Expected effect: vermindering werking foliumzuur |
Interaction with (ATC): L01BA01 - Methotrexate |
Expected effect: verhoging plasmaconcentratie methotrexaat |
Interaction with (ATC): B01AA - Vitamin K Antagonists |
Expected effect: versterking effect orale anticoagulantia |
Pregnancy
Due to the expiration of the alphanumeric classification for use in pregnancy and lactation, reference is made to the current, online information of the Teratology Information Service (TIS) of LAREB:
- http://www.lareb.nl//Teratologie/Naslagwerk-GZB/GZB---Zwangerschap#TOC_Middelen_bij6
- http://www.lareb.nl//Teratologie/Naslagwerk-GZB/GZB---Borstvoeding#TOC_Middelen_bij16
Metadata
Swab vid: M-1291.2
Updated: 06/16/2019 - 20:05
Status: Published